Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 239-245

  Zhang, Tao ^a   Jiang, Tao ^a   Zhang, Feng ^b   Li, Chen ^b   Zhou, Yong An ^a   Zhu, Yi Fang ^a   Li, Xiao Fei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase 3; Non small cell lung cancer; p21Waf1 Cip1 cleavage; Roscovitine

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; GAMMA HISTONE H2AX; HISTONE H2AX; ROSCOVITINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; H2AFX PROTEIN, HUMAN; HISTONE; PURINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; CELL CYCLE; DNA REPAIR; DOSE RESPONSE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LUNG NEOPLASMS; PURINES;

EID: 76049088795     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000629     Document Type: Article

References (23)

1. Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770-1783, 2006.
2. Thomas JP, Tutsch KD, Cleary JF, et al: Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50: 465-472, 2002.
3. Tan AR, Headlee D, Messmann R, et al: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20: 4074-4082, 2002.
4. Benson C, White J, De Bono J, et al: A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96: 29-37, 2007.
5. Meijer L, Borgne A, Mulner O, et al: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536, 1997.
6. Tirado OM, Mateo-Lozano S and Notario V: Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 54: 9320-9327, 2005.
7. Mohapatra S, Chu B, Zhao XH and Pledger WJ: Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 65: 7717-7723, 2005.
8. Wojciechowski J, Horky M, Gueorguieva M and Wesierska-Gadek J: Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106: 486-495, 2002.
9. Mohapatra S, Chu B, Wei S, et al: Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res 63: 8523-8530, 2003.
10. Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E and Lindner H: Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Biochem Pharmacol 76: 1503-1514, 2008.
11. Mihara M, Shintani S, Kiyota A, Matsumura T and Wong DT: Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int J Oncol 21: 95-101, 2002.
12. Zhang F, Zhang T, Gu ZP, et al: Enhancement of radio-sensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. J Radiat Res 49: 541-548, 2008.
13. Lu W, Chen L, Peng Y and Chen J: Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20: 3206-3216, 2001.
14. Demidenko ZN and Blagosklonny MV: Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosisreluctant cells to tumor necrosis factor. Cancer Res 64: 3653-3660, 2004.
15. Schmidt M and Fan Z: Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene 20: 6164-6171, 2001.
16. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
17. waf1/cip1 and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. Carcinogenesis 21: 7-14, 2000.
18. Gervais JL, Seth P and Zhang H: Cleavage of CDK inhibitor p21Cip1/Waf1 by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem 273: 19207-19212, 1998.
19. waf1/cip1 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis 27: 2269-2280, 2006.
20. Zhang F, Zhang T, Teng ZH, Zhang R, Wang JB and Mei QB: Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 8: 823-831, 2009.
21. Xu SQ and El-Deiry WS: p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269: 179-190, 2000.
22. Dong C, Li Q, Lyu SC, Krensky AM and Clayberger C: A novel apoptosis pathway activated by the carboxyl terminus of p21. Blood 105: 1187-1194, 2005.
23. Pan ZQ, Reardon JT, Li L, et al: Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem 270: 22008-22016, 1995.